Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATP2C1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATP2C1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATP2C1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATP2C1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATP2C1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ATP2C1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATP2C1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATP2C1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATP2C1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATP2C1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000724926 | Thyroid | PTC | I-kappaB kinase/NF-kappaB signaling | 130/5968 | 281/18723 | 2.78e-07 | 4.80e-06 | 130 |
GO:1903076112 | Thyroid | PTC | regulation of protein localization to plasma membrane | 58/5968 | 104/18723 | 3.91e-07 | 6.51e-06 | 58 |
GO:004312320 | Thyroid | PTC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 91/5968 | 186/18723 | 8.76e-07 | 1.33e-05 | 91 |
GO:190547725 | Thyroid | PTC | positive regulation of protein localization to membrane | 55/5968 | 106/18723 | 1.45e-05 | 1.55e-04 | 55 |
GO:1904377111 | Thyroid | PTC | positive regulation of protein localization to cell periphery | 37/5968 | 69/18723 | 1.46e-04 | 1.13e-03 | 37 |
GO:1903078110 | Thyroid | PTC | positive regulation of protein localization to plasma membrane | 32/5968 | 62/18723 | 9.64e-04 | 5.77e-03 | 32 |
GO:0048193111 | Thyroid | ATC | Golgi vesicle transport | 189/6293 | 296/18723 | 9.58e-27 | 5.05e-24 | 189 |
GO:1903829210 | Thyroid | ATC | positive regulation of cellular protein localization | 167/6293 | 276/18723 | 3.32e-20 | 5.38e-18 | 167 |
GO:190495128 | Thyroid | ATC | positive regulation of establishment of protein localization | 177/6293 | 319/18723 | 5.43e-16 | 4.29e-14 | 177 |
GO:007265928 | Thyroid | ATC | protein localization to plasma membrane | 161/6293 | 284/18723 | 8.45e-16 | 6.52e-14 | 161 |
GO:009015031 | Thyroid | ATC | establishment of protein localization to membrane | 150/6293 | 260/18723 | 1.05e-15 | 7.96e-14 | 150 |
GO:199077826 | Thyroid | ATC | protein localization to cell periphery | 181/6293 | 333/18723 | 3.72e-15 | 2.56e-13 | 181 |
GO:005122234 | Thyroid | ATC | positive regulation of protein transport | 165/6293 | 303/18723 | 4.94e-14 | 2.69e-12 | 165 |
GO:000689219 | Thyroid | ATC | post-Golgi vesicle-mediated transport | 68/6293 | 104/18723 | 3.30e-11 | 1.10e-09 | 68 |
GO:000689318 | Thyroid | ATC | Golgi to plasma membrane transport | 43/6293 | 60/18723 | 1.85e-09 | 4.53e-08 | 43 |
GO:190437526 | Thyroid | ATC | regulation of protein localization to cell periphery | 74/6293 | 125/18723 | 3.78e-09 | 8.66e-08 | 74 |
GO:1905475111 | Thyroid | ATC | regulation of protein localization to membrane | 96/6293 | 175/18723 | 5.55e-09 | 1.22e-07 | 96 |
GO:009887619 | Thyroid | ATC | vesicle-mediated transport to the plasma membrane | 77/6293 | 136/18723 | 2.86e-08 | 5.43e-07 | 77 |
GO:006195123 | Thyroid | ATC | establishment of protein localization to plasma membrane | 41/6293 | 60/18723 | 4.02e-08 | 7.37e-07 | 41 |
GO:004300117 | Thyroid | ATC | Golgi to plasma membrane protein transport | 30/6293 | 40/18723 | 1.01e-07 | 1.71e-06 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP2C1 | SNV | Missense_Mutation | | c.514N>C | p.Glu172Gln | p.E172Q | P98194 | protein_coding | tolerated(0.17) | benign(0.037) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP2C1 | SNV | Missense_Mutation | | c.2170N>A | p.Glu724Lys | p.E724K | P98194 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP2C1 | SNV | Missense_Mutation | | c.359N>C | p.Leu120Pro | p.L120P | P98194 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ATP2C1 | SNV | Missense_Mutation | | c.1271G>C | p.Gly424Ala | p.G424A | P98194 | protein_coding | tolerated(0.3) | benign(0.406) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ATP2C1 | SNV | Missense_Mutation | | c.1339N>C | p.Asp447His | p.D447H | P98194 | protein_coding | deleterious(0.01) | possibly_damaging(0.81) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ATP2C1 | SNV | Missense_Mutation | rs145949576 | c.1994C>T | p.Ser665Leu | p.S665L | P98194 | protein_coding | deleterious(0) | possibly_damaging(0.611) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP2C1 | insertion | Nonsense_Mutation | novel | c.195_196insTAGAATAAT | p.Val65_Ser66insTer | p.V65_S66ins* | P98194 | protein_coding | | | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
ATP2C1 | deletion | Frame_Shift_Del | | c.685delT | p.Cys229ValfsTer4 | p.C229Vfs*4 | P98194 | protein_coding | | | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP2C1 | deletion | Frame_Shift_Del | | c.340delN | p.Asn115IlefsTer16 | p.N115Ifs*16 | P98194 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATP2C1 | SNV | Missense_Mutation | novel | c.2336C>T | p.Pro779Leu | p.P779L | P98194 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ENFLURANE | ENFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ISOFLURANE | ISOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | SEVOFLURANE | SEVOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ISOFLURANE | ISOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ENFLURANE | ENFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | SEVOFLURANE | SEVOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | DESFLURANE | DESFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | DESFLURANE | DESFLURANE | |